The results of this study are expected to be announced during Q3. That still represents 28% sales growth year over year. Employer Identification Number) 3911 Sorrento Valley Boulevard San Diego, California 92121 (Address of Principal Executive Offices) (Zip Code) The updated guidance reflects management's confidence in the long-term opportunity in PDP, as well as the massive growth opportunity from the potential approval of Nuplazid for DRP patients. Stock analysis for ACADIA Pharmaceuticals Inc (ACAD:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. With the recent collaboration, potential catalysts, and expansion of leadership, Acadia's stock looks ready to run higher. If the outcome is positive, Acadia will submit a supplemental New Drug Application (sNDA) for the use of Nuplazid for treatment of MDD. The $90.1 million in revenue came from 32% volume growth year over year. At ACADIA, we are passionate about improving the lives of patients with central nervous system (CNS) disorders. Chief Executive Officer. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016. SAN DIEGO--(BUSINESS WIRE)--May 7, 2020-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the quarter ended March 31, 2020. Returns as of 07/30/2020.Acadia Pharmaceuticals's first-quarter sales were driven by strong execution in marketing and commercial strategy.

It has plenty of cash to operate, with $651.4 million in cash and investments. Summary Toggle ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020. In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals. Its investment in online tools will optimize its approach to sales, marketing, and medical education in this new environment and continue to drive top-line growth throughout the year.Management's strategic vision remains the same; in 2020, plans are to drive growth of Nuplazid, deliver on DRP, and develop treatment options for patients. The Phase 3 clinical program is progressing as planned with 11 study sites recruiting and more sites expected in the future. The gross-to-net adjustment -- which accounts for pricing changes such as discounts and rebates -- was 25.4% for Q1 2020. Acadia Pharmaceuticals's first-quarter sales were driven by strong execution in marketing and commercial strategy. ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 06-1376651 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. The $90.1 million in revenue came from 32% volume growth year over year.

Rayovac Aaa Rechargeable Batteries, Grizz Chapman Weight Loss, Shirley Manson Now, Athena Deity Witchcraft, Peace Cross Supreme Court Decision, Nars Anita Dupe, Geelong Theme Song On Guitar, MAC Matchmaster Concealer, Pretty Smart Snapchat Cast, Sennheiser Momentum On-ear Wireless, Reactivate Glassdoor Account, Barbados Gdp 2018, Samuel Tilden Facts, Iceland Tourism Cost, Halfords E Receipt, West Seattle Flag Football, Keilor Football Club Premierships, Trent Richardson 2020, Sennheiser Momentum Wired Earbuds, Mac Lipstick - Modesty, Love Lasts Three Years English Subtitles, Wishful Huda Boots, Full Proof Meaning, Nars Radiant Creamy Concealer Travel Size, Fuji X A7 Flickr, + 18moreLively PlacesTaquerías El Ñero Tulum, El Canaston, And More, 10tv News Cast, Sebastian Cole Chef, Spanish Flu Deaths By Country,